These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
398 related items for PubMed ID: 10813279
1. Factors influencing length of time taking methotrexate in rheumatoid arthritis. Ortendahl M, Schettler JD, Fries JF. J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279 [Abstract] [Full Text] [Related]
2. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. Rau R, Schleusser B, Herborn G, Karger T. J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088 [Abstract] [Full Text] [Related]
3. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE. J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365 [Abstract] [Full Text] [Related]
4. The methotrexate therapeutic response in rheumatoid arthritis. Ortendahl M, Holmes T, Schettler JD, Fries JF. J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316 [Abstract] [Full Text] [Related]
5. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA. J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722 [Abstract] [Full Text] [Related]
6. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate. Wolfe F, Michaud K, Stephenson B, Doyle J. J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927 [Abstract] [Full Text] [Related]
7. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice. Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, Littlejohn GO, Miller MH, Ryan PF. J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325 [Abstract] [Full Text] [Related]
8. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial. Matteson EL, Weyand CM, Fulbright JW, Christianson TJ, McClelland RL, Goronzy JJ. Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105 [Abstract] [Full Text] [Related]
9. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. Sokka T, Pincus T. J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145 [Abstract] [Full Text] [Related]
10. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. Hoekstra M, van de Laar MA, Bernelot Moens HJ, Kruijsen MW, Haagsma CJ. J Rheumatol; 2003 Nov; 30(11):2325-9. PubMed ID: 14677172 [Abstract] [Full Text] [Related]
11. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rødevand E, Kaufmann C, Mikkelsen K, Kvien TK. Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904 [Abstract] [Full Text] [Related]
12. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study. Galindo-Rodriguez G, Aviña-Zubieta JA, Russell AS, Suarez-Almazor ME. J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887 [Abstract] [Full Text] [Related]
13. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway. Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC. Scand J Rheumatol; 2009 Nov; 38(4):240-5. PubMed ID: 19229766 [Abstract] [Full Text] [Related]
14. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, Barclay ML. Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853 [Abstract] [Full Text] [Related]
15. Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy. Fries JF, Williams CA, Singh G, Ramey DR. J Rheumatol; 1997 May; 24(5):838-44. PubMed ID: 9150069 [Abstract] [Full Text] [Related]
16. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, Blakely KM, Hausch R, Leff RD. Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240 [Abstract] [Full Text] [Related]
17. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Agarwal S, Zaman T, Handa R. Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623 [Abstract] [Full Text] [Related]
18. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Arthritis Rheum; 2000 Jan; 43(1):22-9. PubMed ID: 10643696 [Abstract] [Full Text] [Related]
19. Therapeutic strategies in rheumatoid arthritis over a 40-year period. Kremers HM, Nicola P, Crowson CS, O'Fallon WM, Gabriel SE. J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636 [Abstract] [Full Text] [Related]
20. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register. Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [Abstract] [Full Text] [Related] Page: [Next] [New Search]